Roche NTproBNP - Leading the Heart Care in T2DM

Dear Dr. Renukaprasad A R, Patients with type 2 diabetes mellitus (T2DM) are more susceptible to the risk of CVD and associated clinical conditions, and it is estimated that up to 46% of T2DM patients will develop some form of CVD during their lifetime.1 ELECSYS NTproBNP is efficient in every stage of cardiac care, is supported by international HF guidelines, and helps with - Diagnosis Assessing the severity Prognosis of HF In this context, read this article decoding the effectiveness of NTproBNP for cardiac care in T2DM patients. Reference: Shah AD et al., Lancet Diabetes Endocrinol. 2015 Feb;3(2):105-13. Click to Read Docplexus is one of the world's largest online communities Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*